Composition with coenzyme Q10 and capsule thereof

A Coenzyme Q10 composition with soy lecithin, DHA, and B vitamins, combined with a protective capsule shell, addresses low absorption and stability issues, enhancing cardiovascular health benefits through improved bioavailability and stability.

DE202024105216U1Active Publication Date: 2024-11-21ZHG NUTRITION & MEDICAL GMBH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
DE202024105216
Authority / Receiving Office
DE · DE
Patent Type
Utility models
Current Assignee / Owner
Filing Date
2024-09-11
Publication Date
2024-11-21
Estimated Expiration
2034-09-30

AI Technical Summary

Technical Problem

Coenzyme Q10 has low absorption rates in the human body and is sensitive to light, limiting its health benefits, particularly in cardiovascular health applications.

Method used

A composition comprising Coenzyme Q10, soy lecithin, DHA, soybean oil, beeswax, and B vitamins, combined with a capsule shell containing gelatin and titanium dioxide, enhances absorption and stability through microbial fermentation and low-temperature extraction, utilizing MPL+ phospholipids technology.

Benefits of technology

The composition achieves a 96% increase in absorption rate and 125-175% improvement in stability and activity of Coenzyme Q10, ensuring high bioavailability and cardiovascular health benefits.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

A composition characterized in that the composition contains: Coenzyme Q10, soy lecithin, soy oil, and B vitamins or pharmaceutically acceptable salts of B vitamins.
Need to check novelty before this filing date? Find Prior Art

Description

Technical area

[0001] The present invention relates to a nutritional preparation, in particular a composition containing coenzyme Q10, and a capsule thereof. State of the art

[0002] Coenzyme Q10 is a chemical component widely distributed in biological cells and has no toxic side effects. It is the basis for energy production in human cells and has a significant metabolic cardiotonic effect. Coenzyme Q10 is mainly used to treat acute and chronic viral hepatitis and acute liver necrosis. It can also be used for the comprehensive treatment of cancer. Coenzyme Q10 also has unique effects in the fields of anti-aging, anti-fatigue, weight loss, and beauty. Coenzyme Q10 is a yellow to orange crystalline powder at room temperature with a low melting point (49 to 52°C), odorless and tasteless, soluble in chloroform, benzene, acetone, diethyl ether, or petroleum ether, and very slightly soluble in ethanol, and insoluble in water and methanol. Coenzyme Q10 is not easily absorbed by the human body and is sensitive to light.

[0003] To maximize the health benefits of coenzyme Q10, scientific technology and scientific formulas are required to enhance the effects of coenzyme Q10, avoid waste, and avoid side effects. Content of the invention

[0004] The purpose of the present invention is to provide a coenzyme Q10 composition that enhances immunity, has a positive effect on cardiovascular diseases, and is easily absorbed by the human body, for example, a coenzyme Q10 capsule.

[0005] The invention is set forth in the appended set of claims.

[0006] The composition of the present invention comprises main components and auxiliary components.

[0007] The main ingredients are coenzyme Q10 and soy lecithin. The main ingredients preferably also contain DHA, such as DHA algal oil.

[0008] The auxiliary ingredients contain soybean oil, optionally also contain beeswax, and preferably also contain B vitamins.

[0009] Preferably, the composition of the present invention contains 30 to 50 wt% coenzyme Q10, preferably 35 to 45 wt% coenzyme Q10, such as 38 wt%, 40 wt%, or 42 wt% coenzyme Q10.

[0010] Preferably, the composition of the present invention contains 15 to 25 wt% soy lecithin, preferably 18 to 22 wt% soy lecithin, such as 19 wt%, 20 wt%, or 21 wt% soy lecithin.

[0011] In addition, the composition of the present invention may also contain 1.5 to 2.5 wt% DHA, such as 1.7 wt%, 2.0 wt%, or 2.2 wt% DHA.

[0012] Preferably, the composition of the present invention contains 30 to 50 wt% soybean oil, preferably 35 to 45 wt% soybean oil, such as 38 wt%, 40 wt%, or 42 wt% soybean oil.

[0013] In addition, the composition of the present invention may also contain 0.8 to 2.0 wt% beeswax, preferably 1.0 to 1.5 wt% beeswax.

[0014] Preferably, the composition of the present invention may also contain 0.5 to 3.0 wt.% of B vitamins or pharmaceutically acceptable salts thereof, preferably 0.8 to 2.0 wt.% of B vitamins or pharmaceutically acceptable salts thereof. The pharmaceutically acceptable salts thereof may be hydrochloride.

[0015] B vitamins act as coenzymes and are involved in many metabolic processes in the body. These include vitamins B1 (thiamine), B2 (riboflavin), B3 (niacin), B4 (6-aminopurine), B5 (pantothenic acid), B6 ​​(pyridoxine), and B12 (cyanocobalamin).

[0016] Preferably, the B vitamins or pharmaceutically acceptable salts thereof in the present invention are riboflavin, pyridoxine hydrochloride and / or thiamine hydrochloride.

[0017] In one embodiment, the composition of the present invention contains 0.5 to 0.7% riboflavin, 0.4 to 0.6% pyridoxine hydrochloride and / or 0.2 to 0.3% thiamine hydrochloride.

[0018] The present invention also provides a capsule containing the above composition as the capsule contents. Furthermore, the capsule has a capsule shell. The capsule shell mainly contains gelatin, glycerin, water, etc.

[0019] For example, the weight ratio of the content composition to the capsule shell is in the range of 1.5:1 to 4:1, for example 6.5:3.5 or 7.0:3.0 or 7.5:2.5.

[0020] The capsule shell of the finished capsule product preferably contains the following components: 50 to 65% by weight gelatin, for example 55% by weight, 57% by weight, 60% by weight, or 62% by weight gelatin; 20 to 40% glycerol, for example 25%, 30%, 33%, or 36% by weight glycerol; 5 to 15% water, for example 7%, 10%, or 12% water by weight.

[0021] In addition, the capsule shell may also contain small amounts of sunscreen, as coenzyme Q10 is easily degraded when exposed to light. The sunscreen may be titanium dioxide, for example. The capsule shell contains, for example, 1 to 3% by weight of titanium dioxide.

[0022] In addition, the capsule shell may also contain small amounts of toner to help tone the capsule. The toner could be, for example, sunset yellow, carotene, chili red, or caramel, etc.

[0023] Preferably, the main ingredient coenzyme Q10 in the present invention is obtained by microbial fermentation technology and uses an industry-leading low-temperature extraction process, thereby ensuring the safety of coenzyme Q10 and further improving the activity and absorption rate of coenzyme Q10.

[0024] Preferably, the present invention can be applied to the introduction by MPL+ phospholipid technology, thereby further improving the absorption rate and bioavailability of coenzyme Q10 activity.

[0025] The advantageous effects of the present invention are as follows: (1) Soy lecithin is a fatty substance obtained from soybeans through an extraction process. It is a natural emulsifier containing essential fatty acids, phospholipids, and choline. Soy lecithin acts as a natural emulsifier and is also rich in essential fatty acids, phospholipids, and choline. One of the main benefits of soy lecithin is its emulsifying ability, which plays a crucial role in fat metabolism. By breaking down fat into smaller particles, it prevents fat from accumulating in the blood vessels, thereby improving blood flow and reducing the risk of cardiovascular problems. Soy lecithin itself has beneficial effects on the cardiovascular system. In combination with coenzyme Q10, which has antioxidant properties, they bring several synergistic health effects for cardiovascular disease. (2) The present invention uses an oil preparation of soybean oil + coenzyme Q10 + soy lecithin + vitamin B. Of these, soybean oil serves as a solvent to assist the dissolution of coenzyme Q10 (coenzyme Q10 itself is oil-soluble). Soy lecithin acts as an emulsifier. After the oil enters the human intestine, it promotes the emulsification of the oil in the intestine (water-soluble system), thereby facilitating the absorption of coenzyme Q10 in the gastrointestinal tract and improving the bioavailability of coenzyme Q10. The vitamin B used in the present invention has a certain degree of fat solubility and a certain degree of water solubility, which helps the oil preparation to be emulsified and water-soluble in the intestinal tract, thereby facilitating the absorption and utilization of all nutrients. (3) The addition of soy lecithin can increase the stability of the oil itself and prevent the precipitation of coenzyme Q10 in soybean oil, thereby ensuring the stability of the oil during production and storage. Furthermore, the addition of beeswax can also increase the stability of the oil itself and prevent coenzyme Q10 from precipitating in soybean oil. (4) Coenzyme Q10 in combination with soy lecithin supports blood flow to the red blood vessels in the heart, achieving a 1+1>2 ratio through a "dual-pronged approach." Combined with soy lecithin, it improves blood flow and protects cardiovascular health. It also accelerates the dissolution and absorption of coenzyme Q10 after it enters the human body, improves the bioavailability of coenzyme Q10, and ensures high stability and activity. This creates the golden triangle in the human body (high purity and activity - high absorption, decomposition and utilization - high stability and easy storage). (5) The coenzyme Q10 oil preparation provided by the present invention has a high coenzyme Q10 content, which can reach 40% or more. At such a high content, it can still remain stable, and crystallization of coenzyme Q10 does not occur above 0°C. This is particularly advantageous for the preparation and preservation of soft capsules. After the oil preparation is prepared as the contents of soft capsules, solid crystals will not precipitate due to environmental changes, which would lead to difficulty in absorption in the human body. (6) The present invention therefore achieves a high coenzyme Q10 content within the capsule. Furthermore, after ingesting the capsule, the dissolution and absorption of coenzyme Q10 is accelerated after entering the human body. The absorption rate of coenzyme Q10 is increased by 96%, and the stability and activity are enhanced by 125% and 175%, respectively. (7) The main ingredient coenzyme Q10 in the present invention is preferably obtained by using microbial fermentation technology and industry-leading low-temperature extraction technology, thereby ensuring the safety of coenzyme Q10 and improving the activity and absorption rate of coenzyme Q10. (8) The present invention can be applied to the introduction by MPL+ phospholipids technology, thereby further improving the absorption rate and bioavailability of coenzyme Q10 activity. Detailed embodiments

[0026] The technical solutions in the embodiments of the present invention are described clearly and completely below. The described embodiments are only some of the embodiments of the present invention and not all of the embodiments. Composition example 1:

[0027] One composition contains: 39% w / w soybean oil, 40% w / w coenzyme Q10, 20% w / w soy lecithin, and 1.0% w / w B vitamins. Composition example 2:

[0028] One composition contains: 37% w / w soybean oil, 40% w / w coenzyme Q10, 20% w / w soy lecithin, 2.0% w / w DHA algae oil and 1.0% w / w B vitamins. Composition example 3:

[0029] A composition contains: 38 wt% soybean oil, 40 wt% coenzyme Q10, 20 wt% soy lecithin, 1.0 wt% B vitamins, and 1.0 wt% beeswax. Composition example 4:

[0030] A composition contains: 36 wt% soybean oil, 40 wt% coenzyme Q10, 20 wt% soy lecithin, 2.0 wt% DHA algae oil, 1.0 wt% B vitamins, and 1.0 wt% beeswax. Capsule comparison example:

[0031] One capsule contains: 28 parts by weight soybean oil, 28 parts by weight coenzyme Q10, 17 parts by weight gelatin, 11 parts by weight glycerin and 1 part by weight water.

[0032] (The content of coenzyme Q10 in each capsule is 200 mg) Capsule example 1:

[0033] One capsule contains: 28 parts by weight soybean oil, 28 parts by weight coenzyme Q10, 14 parts by weight soy lecithin, 17 parts by weight gelatin, 11 parts by weight glycerin, 1 part by weight water, 0.5 parts by weight riboflavin, 0.4 parts by weight pyridoxine hydrochloride, 0.2 parts by weight thiamine hydrochloride.

[0034] (The content of coenzyme Q10 in each capsule is 200 mg) Preparation example:

[0035] The process for producing the above-mentioned Coenzyme Q10 capsules includes the following steps: (1) Preparation of the oil preparation: If the excipient contains beeswax, beeswax and soybean oil are mixed and heated to 60 to 80°C, then cooled to 30 to 50°C. If the excipient does not contain beeswax, the soybean oil is heated to 30 to 50°C. Then, soy lecithin is added to obtain a mixed solution, then coenzyme Q10 is added, and then vitamin B is added. The mixture is stirred evenly to obtain the oil preparation. (2) Preparation of shell solution: Glycerin, purified water, titanium dioxide, etc. are mixed. When heated to 68 to 75 °C, add gelatin, stir, filter through a 100-mesh sieve, let stand, and keep warm at 55 to 60 °C to obtain a shell solution. (3) Pressing: The oil preparation and the shell solution are pressed into capsules at a temperature of 18-26°C and a relative humidity of 45-50% to obtain a soft capsule. (4) Drum drying: mold drying for 10 to 18 hours, drying room temperature 15 to 35 °C, humidity <30%. (5) Sorting: the unqualified products are removed. (6) Packaging and storage. Example of bioavailability:

[0036] A group of 20 healthy adults was randomly selected. Two different capsule formulations (Comparative Capsule Example and Capsule Example 1) were tested on the same group using a crossover / washout approach.

[0037] The bioavailability of various formulations was measured as the area under the curve (AUC) after 48 hours. In coenzyme Q10 research, the AUC of plasma CoQ10 concentration is used to indicate bioavailability, i.e., the proportion of the dose that has entered the circulation.

[0038] After 20 adults took the capsules of Capsule Example 1 for 21 days, the coenzyme content in the body doubled significantly and the coenzyme q10 in the plasma increased significantly.

[0039] Conventional coenzyme Q10 (such as the capsules in the comparative example) only remains in the human body for 8 to 16 hours and develops its effects slowly. After taking the capsule example 1 of the present invention, the absorption rate is 8 times that of the comparative example within 4 hours, 6 times that of the comparative example within 8 hours, and 3.5 times that of the comparative example after 24 hours.

[0040] Due to the good absorption rate and bioavailability of Capsule Example 1 of the present application, coenzyme Q10 can still be detected in plasma even after 36 hours (36 hours after ingestion of the capsule). After ingestion of Capsule Example 1, coenzyme Q10 can remain in the human body for 24 hours and for more than 36 hours.

[0041] The embodiments of the present invention have been described above. Those skilled in the art will understand that various changes, modifications, substitutions, and alterations can be made to these embodiments without departing from the principles and spirit of the present invention. The scope of the invention is defined by the appended claims and their equivalents.

Claims

[1] A composition, characterized by that the composition contains: coenzyme Q10, soy lecithin, soybean oil, and B vitamins or pharmaceutically acceptable salts of B vitamins. [2] Composition according to claim 1, containing 30 to 50 wt.% coenzyme Q10, preferably 35 to 45 wt.% coenzyme Q10. [3] Composition according to claim 1 or 2, containing 15 to 25 wt.% soy lecithin, preferably 18 to 22 wt.% soy lecithin. [4] Composition according to any one of claims 1 to 3, containing 0.5 to 3.0 wt.% of B vitamins or pharmaceutically acceptable salts thereof, preferably 0.8 to 2.0 wt.%. [5] Composition according to any one of claims 1 to 4, wherein the coenzyme Q10 is obtained by microbial fermentation technology and a low-temperature extraction technology. [6] Composition according to any one of claims 1 to 5, also containing DHA, such as DHA algal oil. [7] Composition according to any one of claims 1 to 6, also containing beeswax. [8] A capsule, wherein the capsule has a capsule shell and contains the composition according to any one of claims 1 to 7 as capsule contents. [9] A capsule according to claim 8, wherein the weight ratio of the content composition to the capsule shell is in the range of 1.5:1 to 4:

1. [10] A capsule according to claim 8 or claim 9, wherein the capsule shell contains 50 to 65 wt% gelatin, 20 to 40 wt% glycerol and 5 to 15 wt% water.